Combination of Src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases

A method for the treatment of cancer, which comprises administering to a mammalian specie in need thereof a synergistically, therapeutically effective amount of (1)[1S-[1R*,3R*(E),7R*,10S*,11R*,12R*,16S*]]-7-11dihydroxy-8,8,10,12,16-pentamethyl-3-[1-methyl-2-(2-methyl-4-thiazolyl)ethenyl]-4-aza-17oxabicyclo[14.1.0]heptadecane-5,9-dione and (2) N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide or pharmaceutically acceptable salt thereof, wherein the cancer is selected from prostate cancer or breast cancer.